Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 10/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 10/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 8/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.58 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.45 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Anabasine SCHEMBL15740333 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Dl-Anabasine SCHEMBL30835558 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Dl-Anabasine SCHEMBL117530 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Anabasine SCHEMBL3465120 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| SCHEMBL9673975 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| SCHEMBL9673965 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Anabasine SCHEMBL29421176 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Dl-Anabasine SCHEMBL1004341 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| SCHEMBL6801148 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 | |
| Dl-Anabasine SCHEMBL7194509 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNA7CYP2A6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114831335-A | Application of anabasine in atomized electronic delivery product | 汪冶 | 2022-08-02 | — | — | CN | claimed |
| CN-114732148-A | Application of anabasine in heating non-combustion electron delivery product, solid-state slice and preparation method thereof | 汪冶 | 2022-07-12 | — | — | CN | claimed |
| CN-122030529-A | Traditional Chinese medicine preparation of children's heightening and intelligence-improving beverage and preparation method thereof | 佳乐(山东)控股有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12538922-B2 | Composition and methods for parasite control | PHILIP MORRIS PRODUCTS S.A. (CH) | 2026-02-03 | — | — | US | disclosed |
| US-20250243178-A1 | 3-(1,2,3,6-TETRAHYDROPYRIDIN-2-YL) PYRIDINE GLUTARATE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF | PHILIP MORRIS PRODUCTS S.A. (CH) | 2025-07-31 | — | — | US | disclosed |
| US-12281093-B2 | 3-(1,2,3,6-tetrahydropyridin-2-YL) pyridine glutarate or a pharmaceutically acceptable solvate thereof | PHILIP MORRIS PRODUCTS S.A. (CH) | 2025-04-22 | — | — | US | disclosed |
| CN-115485386-B | Tobacco plant body with low alkaloid content and preparation method thereof | 日本烟草产业株式会社 | 2024-03-29 | — | — | CN | disclosed |
| CN-110072842-B | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-113980978-B | Tobacco nicotine transporter related gene and application thereof | 云南中烟工业有限责任公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-110505874-B | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2023-09-26 | — | — | CN | disclosed |
| US-20220400674-A1 | COMPOSITION AND METHODS FOR PARASITE CONTROL | PHILIP MORRIS PRODUCTS S.A. (CH) | 2022-12-22 | — | — | US | disclosed |
| US-11452293-B2 | (S)-5-ethynyl-anabasine, derivatives thereof, and related compositions and methods of making and using | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| CN-114831335-A | Application of anabasine in atomized electronic delivery product | 汪冶 | 2022-08-02 | — | — | CN | disclosed |
| CN-114732148-A | Application of anabasine in heating non-combustion electron delivery product, solid-state slice and preparation method thereof | 汪冶 | 2022-07-12 | — | — | CN | disclosed |
| EP-3986131-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | Philip Morris Products, S.A. (CH) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281093-B2 | 3-(1,2,3,6-tetrahydropyridin-2-YL) pyridine glutarate or a pharmaceutically acceptable solvate thereof | ADH1A, GRHPR, GLS2 | CHRNB2 3750/4885CHRNA4 2636/4885CHRNA7 2282/4885 |
| US-12538922-B2 | Composition and methods for parasite control | CAT, CTRL, NOX1 | CHRNB2 1244/4885CHRNA4 799/4885CHRNA7 479/4885 |
| US-20220400674-A1 | COMPOSITION AND METHODS FOR PARASITE CONTROL | C5, NOX5, CYCS | CHRNB2 3535/4885CHRNA4 3369/4885CHRNA7 2554/4885 |
| US-20250243178-A1 | 3-(1,2,3,6-TETRAHYDROPYRIDIN-2-YL) PYRIDINE GLUTARATE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF | GLS2, ADH1A, GRHPR | CHRNB2 3588/4885CHRNA4 2543/4885CHRNA7 2183/4885 |
| US-11452293-B2 | (S)-5-ethynyl-anabasine, derivatives thereof, and related compositions and methods of making and using | AAAS, NANS, CIAPIN1 | CHRNB2 2259/4885CHRNA4 2648/4885CHRNA7 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.